Tech Company Financing Transactions

Immuneering Funding Round

Cormorant Asset Management, BlackRock and Lyfe Capital joined a $62 million Series B funding round for Immuneering. This venture round was announced by the company on 1/6/2021.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
Immuneering will use proceeds from the financing to advance to clinical stage programs focused on targets in the RAS/MAPK pathway, a cellular signaling pathway commonly activated in many different tumor types and cancers.

Company Information

Company Status
Mailing Address
245 Main St. 2nd Floor
Cambridge, MA 02142
Email Address
Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.
Immuneering LinkedIn Company Profile
Social Media
Immuneering Company Twitter Account
Company News
Immuneering News
Immuneering on Facebook
Immuneering on YouTube

Management Team

Email & Social
Chief Executive Officer
Benjamin Zeskind
  Benjamin Zeskind LinkedIn Profile  Benjamin Zeskind Twitter Account  Benjamin Zeskind News  Benjamin Zeskind on Facebook
Chief Medical Officer
Scott Barrett
  Scott Barrett LinkedIn Profile  Scott Barrett Twitter Account  Scott Barrett News  Scott Barrett on Facebook
Chief Scientific Officer
Brett Hall
  Brett Hall LinkedIn Profile  Brett Hall Twitter Account  Brett Hall News  Brett Hall on Facebook
Robert Carpenter
  Robert Carpenter LinkedIn Profile  Robert Carpenter Twitter Account  Robert Carpenter News  Robert Carpenter on Facebook
Vice President
Jason Funt
  Jason Funt LinkedIn Profile  Jason Funt Twitter Account  Jason Funt News  Jason Funt on Facebook
Vice President
Peter King
  Peter King LinkedIn Profile  Peter King Twitter Account  Peter King News  Peter King on Facebook
Vice President
Sarah Kolitz
  Sarah Kolitz LinkedIn Profile  Sarah Kolitz Twitter Account  Sarah Kolitz News  Sarah Kolitz on Facebook
Vice President
Andrew Lysaght
  Andrew Lysaght LinkedIn Profile  Andrew Lysaght Twitter Account  Andrew Lysaght News  Andrew Lysaght on Facebook
VP - Bus. Development
Rebecca Kusko
  Rebecca Kusko LinkedIn Profile  Rebecca Kusko Twitter Account  Rebecca Kusko News  Rebecca Kusko on Facebook
VP - R & D
Kevin Fowler
  Kevin Fowler LinkedIn Profile  Kevin Fowler Twitter Account  Kevin Fowler News  Kevin Fowler on Facebook
VP - R & D
Howard Kaufman
  Howard Kaufman LinkedIn Profile  Howard Kaufman Twitter Account  Howard Kaufman News  Howard Kaufman on Facebook



Browse more venture capital transactions:

Prev: 1/6/2021: Botanical Solutions venture capital transaction
Next: 1/6/2021: Aro Biotherapeutics venture capital transaction


Share this article


Where The Data Comes From

We document all VC transactions involving tech companies. VC investment data records on this site come from company press releases and news coverage. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary